Folic Acid (Folic Acid) Patent Expiration, LOE Window & CMS Spending

Folic Acid (Folic Acid) by Eli Lilly: Off-Patent Genericized (AB Competition), 23 AB generics, $39.8M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEli Lilly
FDA Application & PathwayN006135 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors23
2024 CMS Total Public Spend$39.8M
2024 Medicare Part D Spend$7.1M
2024 Medicaid Spend$32.7M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 48.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.